NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103181&from=3 CLASS PERIOD: January 23, 2023 to July ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. and reminds investors of the November 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against the company [1][3]. Group 1: Legal Action and Investor Information - Investors who suffered losses exceeding $50,000 in Agenus between January 23, 2023, and July 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The complaint alleges that Agenus and its executives violated federal securities laws by making false or misleading statements regarding the effectiveness of their combination therapy, botensilimab and balstilimab [3][4]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. Group 2: Company Performance and Stock Impact - On July 18, 2024, Agenus announced that the FDA advised against the submission of clinical results for accelerated approval, leading to a significant stock price drop of $10.43 per share, or 58.83%, closing at $7.30 per share [4]. - The clinical results and regulatory prospects of botensilimab and balstilimab were reportedly overstated, contributing to the misleading public statements made by the company [3].

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. alleging securities fraud that affected investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of their immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - It is alleged that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements by the Company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]. - The firm has over 70 employees and extensive expertise in complex securities litigation [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than previously claimed by the company [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these allegations, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 5, 2024.So What: If you purchased Agenus securities during the Class Period you may ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Investors have until ...

NEWTOWN, Pa., Sept. 11, 2024 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of Agenus, Inc. ("Agenus") (NASDAQ: AGEN) between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").Investors who purchased Agenus stock may move the U.S. District Court for the District of Massachusetts to appoint them as lead plaintiff, no later than November 5, 2024. Please contact Edelson Lechtzin LLP to discuss your inv ...

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for allegedly misleading investors about the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. Allegations - The lawsuit claims that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [2]. - The company's public statements were alleged to be materially false and misleading throughout the class period [2]. Recent Developments - On July 18, 2024, Agenus announced the results of an end-of-Phase 2 meeting with the FDA, which advised against submitting results for Accelerated Approval due to concerns that objective response rates may not translate to survival benefits [3]. - Following this announcement, Agenus's stock price dropped by $10.43 per share, a decline of 58.83%, closing at $7.30 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders since its inception in 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and clinical prospects [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Agenus securities between January 23, 2023, and July 17, 2024 [2]. - Allegations include that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Agenus have until November 5, 2024, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].

NEW YORK, Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both date ...